$SSKN
STRATA Skin Sciences, Inc. Stock $sskn

$sskn Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000119312514102619 Filed on March 17, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013
Revenue	$97.64K	$140.0K	$536.0K
YoY Change	-32.24%	16.67%	92.81%
Cost Of Revenue	$918.5K	-$100.0K	$4.341M
YoY Change	-14.97%	-110.31%	112.59%
Gross Profit	-$820.9K	$240.0K	-$3.805M
YoY Change	-12.31%	-128.24%	115.7%
Gross Profit Margin	-840.74%	171.43%	-709.89%
Selling, General & Admin	$3.200M	$3.100M	$15.54M
YoY Change	-25.41%	-21.52%	9.64%
% of Gross Profit		1291.67%
Research & Development	$707.8K	$540.0K	$3.782M
YoY Change	-43.91%	-58.14%	-44.32%
% of Gross Profit		225.0%
Depreciation & Amortization	$700.0K	$650.0K	$2.434M
YoY Change	40.0%	66.67%	154.34%
% of Gross Profit		270.83%
Operating Expenses	$3.911M	$3.640M	$20.33M
YoY Change	-29.52%	-30.53%	-3.02%
Operating Profit	-$4.732M	-$3.400M	-$24.13M
YoY Change	-27.03%	-44.17%	6.2%
Interest Expense	$1.199K	-$210.0K	$564.0K
YoY Change	-97.54%		1780.0%
% of Operating Profit
Other Income/Expense, Net	-$3.248M	$10.00K	-$1.814M
YoY Change	12286.48%	0.0%	-3588.46%
Pretax Income	-$7.980M	-$4.610M	-$25.95M
YoY Change	22.58%	-24.18%	14.47%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.981M	-$4.610M	-$25.95M
YoY Change	22.56%	-24.18%	14.44%
Net Earnings / Revenue	-8173.66%	-3292.86%	-4841.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.143M	-$5.011M	-$30.17M
COMMON SHARES
Basic Shares Outstanding	47.76M shares	47.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.120M	$3.780M	$3.780M
YoY Change	-62.49%	-51.91%	-51.91%
Cash & Equivalents	$8.123M	$3.783M	$3.780M
Short-Term Investments
Other Short-Term Assets	$470.0K	$880.0K	$880.0K
YoY Change	-46.59%	-9.28%	-9.28%
Inventory	$5.648M	$5.631M	$5.630M
Prepaid Expenses
Receivables	$34.12K	$57.00K	$60.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.27M	$10.35M	$10.35M
YoY Change	-38.31%	6.9%	6.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.995M	$3.691M	$3.690M
YoY Change	-64.76%	-49.78%	-49.8%
Goodwill
YoY Change
Intangibles	$40.53K	$42.00K
YoY Change		-10.64%
Long-Term Investments
YoY Change
Other Assets	$48.00K	$48.00K	$50.00K
YoY Change	-70.0%	-42.86%	-73.68%
Total Long-Term Assets	$3.084M	$3.781M	$3.780M
YoY Change	-64.59%	-50.16%	-50.2%
TOTAL ASSETS
Total Short-Term Assets	$14.27M	$10.35M	$10.35M
Total Long-Term Assets	$3.084M	$3.781M	$3.780M
Total Assets	$17.35M	$14.13M	$14.13M
YoY Change	-45.5%	-18.17%	-18.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.311M	$1.479M	$1.480M
YoY Change	20.29%	-20.05%	-20.0%
Accrued Expenses	$819.9K	$844.0K	$840.0K
YoY Change	-7.88%	-11.72%	-12.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.86M	$5.652M	$5.650M
YoY Change	380.51%	87.21%	87.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$140.0K	$180.0K	$180.0K
YoY Change	-83.53%	-35.71%	-35.71%
Total Long-Term Liabilities	$138.9K	$184.0K	$180.0K
YoY Change	-97.74%	-33.33%	-35.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.86M	$5.652M	$5.650M
Total Long-Term Liabilities	$138.9K	$184.0K	$180.0K
Total Liabilities	$11.00M	$5.836M	$5.840M
YoY Change	30.93%	77.12%	77.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$176.1M	-$168.1M
YoY Change		18.25%
Common Stock	$182.5M	$176.4M
YoY Change		12.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.355M	$8.296M	$8.300M
YoY Change
Total Liabilities & Shareholders Equity	$17.35M	$14.13M	$14.13M
YoY Change	-45.5%	-18.17%	-18.18%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013
OPERATING ACTIVITIES
Net Income	-$7.981M	-$4.610M	-$25.95M
YoY Change	22.56%	-24.18%	14.44%
Depreciation, Depletion And Amortization	$700.0K	$650.0K	$2.434M
YoY Change	40.0%	66.67%	154.34%
Cash From Operating Activities	-$7.120M	-$3.900M	-$19.41M
YoY Change	16.91%	-22.47%	0.99%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$320.0K	$5.188M
YoY Change	-100.0%	-87.15%	-15.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$320.0K	-$5.190M
YoY Change	-100.0%	-87.15%	-15.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$11.46M		$21.17M
YoY Change	-27.22%		307.04%
Debt Paid & Issued, Net			$6.425M
YoY Change
Cash From Financing Activities	11.46M	5.380M	20.52M
YoY Change	-46.75%	153.77%	290.86%
NET CHANGE
Cash From Operating Activities	-7.120M	-3.900M	-19.41M
Cash From Investing Activities	0.000	-320.0K	-5.190M
Cash From Financing Activities	11.46M	5.380M	20.52M
Net Change In Cash	4.340M	1.160M	-4.080M
YoY Change	-68.53%	-121.48%	-79.73%
FREE CASH FLOW
Cash From Operating Activities	-$7.120M	-$3.900M	-$19.41M
Capital Expenditures	$0.00	-$320.0K	$5.188M
Free Cash Flow	-$7.120M	-$3.580M	-$24.60M
YoY Change	-7.91%	40.94%	-3.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	900000	shares
CY2013Q3	mela	Common Stock Minimum Bid Price CommonStockMinimumBidPrice	1.00
CY2013Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.85
CY2013Q4	mela	Aggregate Consideration Receivable For Warrants To Be Issued AggregateConsiderationReceivableForWarrantsToBeIssued	6857142	shares
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47755791	shares
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5300000
CY2013Q1	mela	Fair Value Of Warrant Obligation FairValueOfWarrantObligation	563000
CY2013Q2	dei	Entity Public Float EntityPublicFloat	39730954
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4228181	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.35
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.01
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2057104	shares
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	29807000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27997000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32204720	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32204720	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.62
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2426533	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.99
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	956000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2969000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1850000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56182000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3019000
CY2012Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	60000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	13975000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	156143000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2012Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142200000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	172000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	144000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	32000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17270000
CY2012Q4	us-gaap	Liabilities Liabilities	3295000
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	276000
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	132000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Assets Current AssetsCurrent	9683000
CY2012Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	26511000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	47000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	84000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26471000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56182000
CY2012Q4	us-gaap	Assets Assets	17270000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	3200000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7862000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	180000
CY2012Q4	us-gaap	Inventory Net InventoryNet	676000
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10319000
CY2012Q4	us-gaap	Inventory Gross InventoryGross	676000
CY2012Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	106000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	965000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7350000
CY2012Q4	mela	Aggregate Intrinsic Value Exercised AggregateIntrinsicValueExercised	17000
CY2012Q4	mela	Property Plant And Equipment Capitalized Costs PropertyPlantAndEquipmentCapitalizedCosts	6158000
CY2012Q4	mela	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberVested	1620320	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47501596	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1261355	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47501596	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3065714	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3729853	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.56
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3065714	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.85
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	844000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	478000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5403000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1433000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1479000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66561000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5652000
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3017000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2013Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	33000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	8296000
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	176396000
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	46000
CY2013Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	48000
CY2013Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	3017000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168148000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	244000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	120000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	48000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14132000
CY2013Q4	us-gaap	Liabilities Liabilities	5836000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	477000
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	184000
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	68000
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	64000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	478000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	10351000
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	27794000
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	42000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35086000
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66561000
CY2013Q4	us-gaap	Assets Assets	14132000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	3681000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3783000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	57000
CY2013Q4	us-gaap	Inventory Net InventoryNet	5631000
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	325000
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9094000
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	87000000
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	727000
CY2013Q4	us-gaap	Inventory Gross InventoryGross	5956000
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	880000
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	755000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3691000
CY2013Q4	mela	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Non Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonVested	1804359	shares
CY2013Q4	mela	Warrants Issued WarrantsIssued	12093591	shares
CY2013Q4	mela	Property Plant And Equipment Capitalized Costs PropertyPlantAndEquipmentCapitalizedCosts	5188000
CY2013Q4	mela	Working Capital WorkingCapital	4699000
CY2013Q4	mela	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberVested	1261355	shares
CY2013Q3	mela	Nasdaq Minimum Price Bid Requirement Grace Period NasdaqMinimumPriceBidRequirementGracePeriod	P180D
CY2013Q3	mela	Number Of Consecutive Business Days Not Complied With Minimum Bid Price NumberOfConsecutiveBusinessDaysNotCompliedWithMinimumBidPrice	P30D
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	900000	shares
CY2013Q2	mela	Additional Stock Based Compensation Expenses AdditionalStockBasedCompensationExpenses	423000
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	983000
CY2013Q4	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2013Q4	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.9478	pure
CY2013Q4	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0131	pure
CY2013Q4	mela	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	5500000
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.35
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.91
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.44
CY2011	mela	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted	P9Y6M
CY2013	dei	Trading Symbol TradingSymbol	MELA
CY2013	dei	Entity Registrant Name EntityRegistrantName	MELA SCIENCES, INC. /NY
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001051514
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2013	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y3M29D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.72	pure
CY2013	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.9343	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>1. Company</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the commercialization of our flagship product, MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> , the further design and development of MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> and our technology. MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that were ‘trained’ on our proprietary database of melanomas and benign lesions. This then provides information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The components of the MelaFind<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> system include:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">a <i>hand-held component</i>, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">a <i>proprietary database</i> of pigmented skin lesions, believed to be the largest positive prospective database to date in the U.S.; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left"><i>lesion classifiers</i>, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval for MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>. On March 7, 2012, the Company installed the first commercial MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> systems, and proceeded with the commercial launch of MelaFind <sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>. We are currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using MelaFind<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> In 2012 the Company evolved from a research and development company to a commercial enterprise. The launch of MelaFind<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> in 2012, and the subsequent commercialization activities following the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. Our cash used in operating activities for the year ended December 31, 2013 and December 31, 2012 totaled $19,413 and $19,224, respectively, and net revenues totaled $536 and $278, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> In mid 2013, a significant cost reduction program was put into place (see Note 16). On November 11, 2013, a new CEO was brought on board and a newly refocused “Go-to-Market” strategy focusing on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma was adopted. As part of this strategy, in late December, we elected to change our business model from a rental to a sale model for the MelaFind<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> device. The Company has reduced its costs, brought new and experienced talent to its management team and has reconsidered the approach to the commercialization of the MelaFind<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> device. The Company has also begun the process of obtaining a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, in order to obtain reimbursement by Medicare for use of the MelaFind<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> device. The Company anticipates that this process could take up to two years. Once a coverage determination has been made, the Company plans to seek reimbursement by Medicaid, Medicare and other third-party payers.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> On August 22, 2013, the Company received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, the Company was not in compliance with a Nasdaq rule for continued listing that requires a listed company’s common stock to maintain a minimum bid price of $1.00 per share. The Company was granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, we were notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> On October 17, 2013, the FDA sent the Company a letter stating the information in the August 8, 2013 progress report with respect to the PAS was inadequate to allow the agency to complete its review and therefore the FDA asked for additional information. Because of rate of accrual issues, the FDA’s letter informed the Company that its study status was revised on the FDA’s website to “Progress Inadequate.” On September 9, 2013, the Company placed this study on hold to investigate enrollment. On November 15, 2013, the Company responded to the FDA’s letter, outlining an enrollment plan as well as a new enrollment schedule. On January 2, 2014, the FDA prompted an interactive review process to obtain further additional information regarding the Company’s response. On January 13, 2014, the Company’s enrollment plan and enrollment schedule was approved by the FDA and the interactive review process was closed as the FDA deemed the Company has sufficiently met the reporting expectations of the report. The Company’s new study timeline was approved for study restart in January 2014, steps to restart the study have been initiated. The FDA noted in their January 13, 2014 email that the status would remain as “Progress Inadequate” and that the status would be reassessed upon review of the next interim report date, February 8, 2014, based on the newly approved January 2014 restart timeline. As of the Company’s February 24, 2014 teleconference with the FDA, they noted that they have not had time to read our February 8, 2014 report and therefore the status has not been reviewed.</p> </div>
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42894500	shares
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19413000
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.60
CY2013	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0175	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4994465	shares
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.77	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	4337225	shares
CY2013	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.65
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0071	pure
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18059	shares
CY2013	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	Greater than fifty percent
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15258680	shares
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The Company performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for uncollectible accounts receivable based upon the expected collectability of all accounts receivable.</p> </div>
CY2013	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	652000	shares
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.</p> </div>
CY2013	us-gaap	Open Tax Year OpenTaxYear	2009
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21174000
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	8822000
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	4341000
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3782000
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	27000
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4079000
CY2013	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	41000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5188000
CY2013	us-gaap	Interest Expense InterestExpense	564000
CY2013	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	10.35
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0245	pure
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-86000
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	0
CY2013	us-gaap	Gross Profit GrossProfit	-3805000
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6425000
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-36000
CY2013	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-296000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-24134000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-77000
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1814000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-25948000
CY2013	us-gaap	Defined Benefit Plan Special Termination Benefits DefinedBenefitPlanSpecialTerminationBenefits	100000
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-121000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1301000
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	20000
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	536000
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15725000
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5188000
CY2013	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	5755000
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-484000
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1011000
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	296000
CY2013	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-24000
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15536000
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10379000
CY2013	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	1557000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20522000
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1301000
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2439000
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	250000
CY2013	us-gaap	Depreciation Depreciation	2434000
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	509000
CY2013	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	18000
CY2013	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	136000
CY2013	us-gaap	Operating Expenses OperatingExpenses	20329000
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2013	mela	Unrecognized Tax Benefits Recognition Description UnrecognizedTaxBenefitsRecognitionDescription	Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.
CY2013	mela	Associated Revenue Over Related Service Period AssociatedRevenueOverRelatedServicePeriod	Generally expected to be two years
CY2013	mela	Bad Debt Expense BadDebtExpense	46000
CY2013	mela	Income Tax Benefit Recognition Criteria Percentage Threshold IncomeTaxBenefitRecognitionCriteriaPercentageThreshold	0.50	pure
CY2013	mela	Share Based Compensation Requisite Service Period Yet To Be Recognized Value ShareBasedCompensationRequisiteServicePeriodYetToBeRecognizedValue	447000
CY2013	mela	Amount Reclassified From Warrant Liability To Equity AmountReclassifiedFromWarrantLiabilityToEquity	652000
CY2013	mela	Liquidation Damages Percentage LiquidationDamagesPercentage	0.320	pure
CY2013	mela	Noncancellable Operating Leases Term Of Expiration NoncancellableOperatingLeasesTermOfExpiration	2016-12
CY2013	mela	Write Off Of Unamortized Loan Costs WriteOffOfUnamortizedLoanCosts	983000
CY2013	mela	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period For Directors ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriodForDirectors	P1Y
CY2013	mela	Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodMaximum	P10Y
CY2013	mela	Lapsing Of Restrictions Related To Restricted Stock Issued Start Date LapsingOfRestrictionsRelatedToRestrictedStockIssuedStartDate	2013-04-25
CY2013	mela	Fair Value Assumptions Treasury Yield Period FairValueAssumptionsTreasuryYieldPeriod	P5Y
CY2013	mela	Liquid Investments Maturity Period To Be Classified As Cash Equivalent Maximum LiquidInvestmentsMaturityPeriodToBeClassifiedAsCashEquivalentMaximum	Three months or less
CY2013	mela	Reclassification Of Property And Equipment To Inventory ReclassificationOfPropertyAndEquipmentToInventory	5402000
CY2013	mela	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	2573000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30762610	shares
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.46
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19224000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.28
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.00
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	863202	shares
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	431977	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0091	pure
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	61796	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.77
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2626533	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0160	pure
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-96000
CY2012	us-gaap	Gross Profit GrossProfit	-1764000
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	45000
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	32000
CY2012	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	1360000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5247000
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	20000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-22725000
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	303000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	86000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1488000
CY2013Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	6400000
CY2012	us-gaap	Interest Paid InterestPaid	41000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	180000
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	52000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-22673000
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	676000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1488000
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	20000
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	278000
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5308000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6158000
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1390000
CY2012	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	6000
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14169000
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9069000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	970000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-20135000
CY2012	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	62000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6158000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5202000
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	7709000
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	2042000
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6792000
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	10000
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	45000
CY2012	us-gaap	Depreciation Depreciation	957000
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	483000
CY2012	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	45000
CY2012	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	151000
CY2012	us-gaap	Operating Expenses OperatingExpenses	20961000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2012	mela	Stock Issued During Period Value Stock Options Exercised Cashless StockIssuedDuringPeriodValueStockOptionsExercisedCashless
CY2012	mela	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted	P9Y6M
CY2012	mela	Reclassification From Other Assets To Property And Equipment ReclassificationFromOtherAssetsToPropertyAndEquipment	522000
CY2012	mela	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period For Directors ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriodForDirectors	P1Y
CY2012	mela	Aggregate Intrinsic Value For Forfeited Or Expired AggregateIntrinsicValueForForfeitedOrExpired	27000

Files In Submission

Name	View Source	Status
0001193125-14-102619-index-headers.html	Edgar Link	pending
0001193125-14-102619-index.html	Edgar Link	pending
0001193125-14-102619.txt	Edgar Link	pending
0001193125-14-102619-xbrl.zip	Edgar Link	pending
d662215d10k.htm	Edgar Link	pending
d662215dex101.htm	Edgar Link	pending
d662215dex1023.htm	Edgar Link	pending
d662215dex231.htm	Edgar Link	pending
d662215dex311.htm	Edgar Link	pending
d662215dex312.htm	Edgar Link	pending
d662215dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mela-20131231.xml	Edgar Link	completed
mela-20131231.xsd	Edgar Link	pending
mela-20131231_cal.xml	Edgar Link	unprocessable
mela-20131231_def.xml	Edgar Link	unprocessable
mela-20131231_lab.xml	Edgar Link	unprocessable
mela-20131231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSKN
STRATA Skin Sciences, Inc. Stock $sskn

2014 Q1 Form 10-K Financial Statement

#000119312514102619 Filed on March 17, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSKN STRATA Skin Sciences, Inc. Stock $sskn

2014 Q1 Form 10-K Financial Statement

#000119312514102619 Filed on March 17, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSKN
STRATA Skin Sciences, Inc. Stock $sskn